Duchenne Muscular Dystrophy Pipeline Review, H2 2020: Therapeutics Assessment, Competitive Landscape, Drug Profiles, Dormant Projects – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Duchenne Muscular Dystrophy – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 5, 14, 11, 1, 59, 22 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 12 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. (Read more…)
• Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

• Duchenne Muscular Dystrophy – Overview
• Duchenne Muscular Dystrophy – Therapeutics Development

Duchenne Muscular Dystrophy – Therapeutics Assessment

Duchenne Muscular Dystrophy – Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy – Drug Profiles

Duchenne Muscular Dystrophy – Dormant Projects

• Duchenne Muscular Dystrophy – Discontinued Products
• Duchenne Muscular Dystrophy – Product Development Milestones

Appendix

Companies Mentioned

• 4D Molecular Therapeutics Inc
• AAVogen Inc
• Akashi Therapeutics Inc
• Alpha Anomeric
• American CryoStem Corp
• Anagenesis Biotechnologies SAS
• Antisense Therapeutics Ltd
• Armgo Pharma Inc
• Audentes Therapeutics Inc
• AUM LifeTech Inc
• Avidity Biosciences Inc
• Axolo Pharma Inc
• Biogen Inc
• BioIncept LLC
• Bioleaders Corp
• Biophytis SA
• Capricor Therapeutics Inc
• Catabasis Pharmaceuticals Inc
• Consortium.AI
• Constant Therapeutics LLC
• CRISPR Therapeutics AG
• Cumberland Pharmaceuticals Inc
• Daiichi Sankyo Co Ltd
• DepYmed Inc
• DMD Therapeutics Inc
• DTx Pharma Inc
• Dyne Therapeutics Inc
• Dystrogen Therapeutics SA
• Edgewise Therapeutics
• Editas Medicine Inc
• Eloxx Pharmaceuticals Inc
• Epirium Bio Inc
• Evox Therapeutics Ltd
• FibroGen Inc
• FibroGenesis LLC
• Fulcrum Therapeutics Inc
• Galapagos NV
• GlaxoSmithKline Plc
• InnoBioscience LLC
• Italfarmaco SpA
• Ixchel Pharma LLC
• Keros Therapeutics Inc
• LambdaGen Therapeutics
• Milo Biotechnology LLC
• Mitobridge Inc
• Mitochon Pharmaceuticals Inc
• MyoGene Bio LLC
• Myos Inc
• Myosana Therapeutics Inc
• MyoTherix Inc
• Nippon Shinyaku Co Ltd
• OliPass Corporation
• Oncotelic Inc
• Pepgen Ltd
• PeptiDream Inc
• Pfizer Inc
• PhaseBio Pharmaceuticals Inc
• Pliant Therapeutics Inc
• Progenitor Therapeutics Ltd
• Prothelia Inc
• PTC Therapeutics Inc
• PYCTX Ltd
• RASRx LLC
• ReveraGen BioPharma Inc
• Ridgeline Therapeutics LLC
• Santhera Pharmaceuticals Holding AG
• Sarcomed AB
• Sarepta Therapeutics Inc
• Solid Biosciences Inc
• SOM Biotech SL
• Stealth BioTherapeutics Corp
• SteroTherapeutics LLC
• Sutura Therapeutics Ltd
• Taiho Pharmaceutical Co Ltd
• Teijin Pharma Ltd
• Tivorsan Pharmaceuticals Inc
• Tolerion Inc
• UGISense AG
• Vertex Pharmaceuticals Inc
• Vita Therapeutics Inc
• Zata Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f0u2ly

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900